




Instance: composition-en-08cf6fb4c3e579390e3141196404b03b
InstanceOf: CompositionUvEpi
Title: "Composition for quadramet Package Leaflet"
Description:  "Composition for quadramet Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp08cf6fb4c3e579390e3141196404b03b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - quadramet"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet:</p>
<ol>
<li>What Quadramet is and what it is used for </li>
<li>What you need to know before you take Quadramet </li>
<li>How to take Quadramet </li>
<li>Possible side effects </li>
<li>How to store Quadramet </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What quadramet is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What quadramet is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Quadramet is a medicinal product for therapeutic use only. </p>
<p>This radiopharmaceutical is used for the treatment of bone pain due to your disease. </p>
<p>Quadramet has a high affinity for skeletal tissue. Once injected it concentrates in bone lesions. 
Because Quadramet contains small amounts of a radioactive element, samarium-153, radiations are 
delivered locally to the bone lesions, allowing to develop the palliative action on bone pain. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take quadramet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take quadramet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Quadramet: 
* If you are allergic to ethylene diamine tetramethylene phosphonic acid (EDTMP) or similar 
phosphonate compounds or any of the other ingredients of this medicine (listed in section 6), 
* If you are pregnant, 
* If you have received chemotherapy or hemibody field external radiation therapy in a preceding 
period of 6 weeks. </p>
<p>Warnings and precautions 
Talk to your doctor before taking Quadramet. </p>
<p>Your doctor will take blood samples weekly for at least 8 weeks to check your platelets, white and red 
blood cell counts which may slightly decrease due to the therapy. </p>
<p>During 6 hours following the injection of Quadramet, your physician will encourage you to drink and 
void as often as possible. He will decide at which time you will be authorised to leave the nuclear 
medicine department. </p>
<p>In the case of urine incontinence or urinary obstruction you will get a urine catheter for about 6 hours. 
For the other patients the urine should be collected for at least 6 hours. </p>
<p>If your renal function is decreased, the amount of product will be adapted. </p>
<p>Children and adolescents 
Quadramet is not recommended for use in children below 18 years of age. </p>
<p>Other medicines  and Quadramet 
Tell your doctor if you are taking or have recently taken or might take any other medicines. </p>
<p>Pregnancy and breast-feeding: 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor for advice before taking this medicine. </p>
<p>Quadramet must not be administered to pregnant women. 
If Quadramet administration to a breastfeeding woman is deemed necessary, breastfeeding should be 
stopped. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take quadramet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take quadramet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Your doctor will want to carry out a special scan before administering Quadramet to ascertain whether 
you are likely to benefit from Quadramet. </p>
<p>Dosage 
One single dose of 37 megabecquerel (Becquerel is the unit in which radioactivity is measured) of 
Quadramet per kilogram of body weight is to be injected. 
If you have the impression that the effect of Quadramet is too strong or too weak, talk to your doctor 
or pharmacist. 
Method and route of administration 
Quadramet is to be administered by slow injection into a vein. 
Frequency of administration 
This medicinal product is not intended to be injected on a regular or continuous basis. The 
administration can however be repeated after 8 weeks following injection, subject to the evolution of 
your disease. 
Duration of treatment 
You will be authorised to leave the nuclear medicine department after a dosimetric follow-up 
(generally within 6 hours following Quadramet injection). 
If you take more Quadramet than you should 
Quadramet being supplied as a single-dose vial, an accidental overdose is unlikely to occur. 
Radiation dose to the body can be limited by increasing fluid intake and frequent voiding of urine. 
If you have any further questions on the use of this product, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The undesirable effects due to Quadramet administration are linked with a decrease of red and white 
blood cells, and platelets. Cases of bleeding have been reported, some of which have been serious. </p>
<p>This is the reason why your blood counts will be monitored strictly for a few weeks following 
Quadramet injection. </p>
<p>You may exceptionally feel a slight increase in bone pain a few days after Quadramet injection. You 
should not be alarmed at this; in such case, your pain medicine will be slightly increased. This effect is 
moderate and brief and will disappear after some hours. </p>
<p>Adverse drug reactions such as nausea, vomiting, diarrhoea and sweating were reported. </p>
<p>Hypersensitivity reactions including rare cases of anaphylactic reaction have been reported after 
Quadramet administration. </p>
<p>In rare cases, the following undesirable effects have been observed: neuralgia, coagulation disorders, 
cerebrovascular accidents. These effects were deemed to be related to the progression of the disease. </p>
<p>If you experience back pain or sensory abnormalities, please inform your physician as soon as 
possible. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects you can help provide more information on the safety of 
this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store quadramet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store quadramet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use Quadramet after the expiry date which is stated on the label. 
Quadramet expires 1 day from the activity reference time stated on the label. </p>
<p>Store at  10 C to  20 C in a freezer in its original packaging. </p>
<p>Quadramet should be used within 6 hours of thawing. After thawing, do not freeze again. </p>
<p>The product label includes the appropriate storage conditions and the expiry date for the batch of 
product. Hospital personnel will ensure that the product is stored correctly and not administered to you 
after the stated expiry date. </p>
<p>Storage procedures should be in accordance with national regulations for radioactive materials. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Quadramet contains 
The active substance is samarium (153Sm) lexidronam pentasodium. 
Each ml of solution contains 1.3 GBq Samarium (153Sm) lexidronam pentasodium at the reference date 
(corresponding to 20-80  g/ml of samarium per vial). </p>
<p>The other ingredients are total EDTMP (as EDTMP.H2O), calcium-EDTMP sodium salt (as Ca), total 
sodium (as Na), water for injections. </p>
<p>What Quadramet looks like and contents of the pack 
Quadramet is a solution for injection. </p>
<p>This medicinal product is a clear, colourless to light amber solution which is packed in a 15 ml 
colourless European Pharmacopoeia Type I drawn glass vial closed with Teflon-coated 
chlorobutyl/natural rubber stopper and aluminium flip-off overseal. </p>
<p>Each vial contains 1.5 ml (2 GBq at reference) to 3.1 ml (4 GBq at reference) of solution for injection. </p>
<p>Marketing authorisation holder and manufacturer </p>
<p>CIS bio international 
Bo te Postale F-91192 Gif-sur-Yvette cedex 
France </p>
<p>The leaflet was last revised in {MM/YYYY} </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-08cf6fb4c3e579390e3141196404b03b
InstanceOf: CompositionUvEpi
Title: "Composition for quadramet Package Leaflet"
Description:  "Composition for quadramet Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp08cf6fb4c3e579390e3141196404b03b)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - quadramet"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen: 
1. Virkning og anvendelse 
2. Det skal De vide, før De begynder at bruge Quadramet 
3. Sådan skal De bruge Quadramet 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What quadramet is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What quadramet is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lægemidlet Quadramet er kun til terapeutisk brug. </p>
<p>Dette radioaktive lægemiddel anvendes til behandling af knoglesmerter, som er forårsaget af Deres 
sygdom. </p>
<p>Quadramet har en høj affinitet for knoglevæv. Når det er injiceret, koncentrerer det sig i 
knoglelæsionerne. Da Quadramet indeholder små mængder af et radioaktivt grundstof, samarium 153, 
afgives der bestråling lokalt til knoglelæsionerne, hvorved der sker lindring af knoglesmerter. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take quadramet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take quadramet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Quadramet, </p>
<ul>
<li>
<p>hvis De er allergisk over for ethylendiamintetramethylenfosfonsyre (EDTMP) eller lignende 
fosfonatforbindelser eller et af de øvrige indholdsstoffer i Quadramet (angivet i punkt 6), </p>
</li>
<li>
<p>hvis De er gravid, </p>
</li>
<li>
<p>hvis De har modtaget kemoterapi eller ekstern halvkropsbestrålingsbehandling inden for 6 uger 
før. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før De bruger Quadramet.<br />
Deres læge vil tage blodprøver en gang om ugen i mindst 8 uger for at kontrollere antallet af Deres 
blodplader samt hvide og røde blodlegemer, som kan falde lidt på grund af behandlingen. </p>
<p>Deres læge vil anbefale Dem at indtage drikkevarer og tømme deres blære så ofte som muligt i de 
første 6 timer efter Quadramet injektionen. Lægen vil beslutte, på hvilket tidspunkt De vil få tilladelse 
til at forlade den nuklearmedicinske afdeling. </p>
<p>I tilfælde af urininkontinens eller urinrørsobstruktion vil De have et urinkateter indlagt i cirka 6 timer. 
For andre patienter bør urinen opsamles i mindst 6 timer. </p>
<p>Hvis Deres nyrefunktion er nedsat, vil mængden af den medicin De modtager, blive tilpasset hertil.  </p>
<p>Børn og teenagere 
Quadramet er ikke anbefalet til brug hos børn under 18 år. </p>
<p>Brug af anden medicin sammen med Quadramet 
Fortæl altid lægen eller på apoteket, hvis De bruger anden medicin eller har gjort det for nylig. Dette 
gælder også medicin, som ikke er købt på recept. </p>
<p>Graviditet og amning 
Hvis De er gravid eller ammer, har mistanke om, at De er gravid, eller planlægger at blive gravid, skal 
De spørge Deres læge til råds, før De bruger dette lægemiddel. </p>
<p>Quadramet må ikke indgives til gravide kvinder. 
Hvis det er nødvendigt at indgive Quadramet til en kvinde, der ammer, bør amningen standses. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take quadramet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take quadramet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Deres læge vil udføre en speciel scanning inden indgivelse af Quadramet for at undersøge, hvorvidt 
der er sandsynlighed for, at De vil få gavn af Quadramet. </p>
<p>Dosering 
Én enkelt dosis på 37 megaBecquerel (Becquerel er den enhed, der anvendes til måling af 
radioaktiviteten) Quadramet pr. kilogram legemsvægt injiceres. 
Hvis De mener, at virkningerne af Quadramet er for kraftige eller for svage, bør De tale med Deres 
læge eller apotek herom. </p>
<p>Anvendelsesmåde og indgivelsesvej 
Quadramet skal indgives ved langsom injektion ind i en vene. </p>
<p>Hyppighed samt korrekt tidspunkt for indgivelse 
Dette lægemiddel er ikke beregnet til at blive injiceret regelmæssigt eller vedvarende. Indgivelsen kan 
imidlertid gentages 8 uger efter injektionen, afhængigt af hvordan Deres sygdom har udviklet sig. </p>
<p>Behandlingens varighed 
De vil få lov til at forlade den nuklearmedicinske afdeling efter en dosimetrisk opfølgning (normalt 
inden for 6 timer efter injektionen med Quadramet). </p>
<p>Hvis De har brugt for meget QUADRAMET 
Da Quadramet leveres i hætteglas med én dosis, er det ikke sandsynligt, at der vil ske en utilsigtet 
overdosering. Strålingsdosen til Deres krop kan begrænses ved at forøge væskeindtagelsen samt ved 
hyppig udtømning af urin. </p>
<p>Spørg lægen eller på apoteket, hvis der er noget, De er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Bivirkningerne fra indgivelse af Quadramet er sammenkædet med en nedgang i antallet af røde og 
hvide blodlegemer og blodplader. Tilfælde af blødninger er rapporteret, hvoraf nogle har været 
alvorlige.  </p>
<p>Dette er grunden til, at Deres blodtællinger vil blive overvåget strengt i nogle få uger efter injektionen 
med Quadramet. </p>
<p>De kan i sjældne tilfælde opleve let forøgede knoglesmerter nogle få dage efter injektionen med 
Quadramet. De skal ikke være urolig over dette; i sådant tilfælde vil Deres medicin blive let øget. 
Bivirkningen er moderat og kortvarig og vil forsvinde efter nogle timer. </p>
<p>Bivirkninger, såsom kvalme, opkastning, diarré og svedafsondring, blev rapporteret. </p>
<p>Overfølsomhedsreaktioner, herunder sjældne tilfælde af anafylaktisk reaktion, er rapporteret efter 
indgivelse af Quadramet. </p>
<p>I sjældne tilfælde er følgende bivirkninger blevet observeret: Neuralgi, koagulationsforstyrrelser og 
cerebrovaskulære hændelser. Disse bivirkninger blev regnet som relateret til sygdomsudviklingen. </p>
<p>Hvis De oplever smerte i ryggen eller forstyrrelser af sanserne, bør De så hurtigt som muligt 
underrette Deres læge herom. </p>
<p>Indberetning af bivirkninger<br />
Hvis De oplever bivirkninger, bør De tale med Deres læge eller apoteket. Dette gælder også mulige 
bivirkninger, som ikke er medtaget i denne indlægsseddel. De eller Deres pårørende kan også 
indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan De hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store quadramet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store quadramet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar dette lægemiddel utilgængeligt for børn. </p>
<p>Brug ikke Quadramet efter den udløbsdato, der står på etiketten. 
Quadramet udløber 1 dag efter aktivitetens referenceklokkeslæt, som er angivet på etiketten. </p>
<p>Opbevares ved -10°C til -20°C i dybfryser i den originale emballage. </p>
<p>Quadramet bør bruges inden for 6 timer efter optøning. Må ikke nedfryses igen efter optøning. </p>
<p>Dette produkts etikette angiver korrekte opbevaringsforhold samt udløbsdato for produktets batch. 
Hospitalets personale vil sikre, at produktet er opbevaret korrekt og ikke indgives til Dem efter den 
angivne udløbsdato. </p>
<p>Opbevaringsprocedurerne bør være i overensstemmelse med nationale regulativer for radioaktive 
materialer. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Quadramet indeholder 
- Aktivt stof: samarium (153Sm) lexidronam pentanatrium. 
Hver ml opløsning indeholder 1,3 GBq samarium (153Sm) lexidronam pentanatrium på referencedato. 
(svarende til 20-80 µg/ml samarium pr. hætteglas). </p>
<ul>
<li>Øvrige indholdsstoffer: total EDTMP (som EDTMP·H2O), calcium-EDTMP natriumsalt (som 
Ca), total natrium (som Na), vand til injektioner. </li>
</ul>
<p>Udseende og pakningsstørrelser 
Quadramet er en opløsning til injektion. </p>
<p>Denne medicin er en klar, farveløs til lysegul opløsning, som er emballeret i et 15 ml klart Europæisk 
Farmakopé Type I trukket hætteglas, lukket med Teflon-belagt chlorobutyl/naturgummi-lukning og en 
ydre afrivningsforsegling af aluminium. </p>
<p>Hvert hætteglas indeholder 1,5 ml (2 GBq på referencedato) til 3,1 ml (4 GBq på referencedato.) 
injektionsvæske. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<p>CIS bio international 
Boîte Postale F-91192 Gif-sur-Yvette cedex 
Frankrig </p>
<p>Denne indlægsseddel blev senest ændret {MM/ÅÅÅÅ} </p>
<p>De kan finde yderligere information om Quadramet på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu/ </p>
<p>Følgende oplysninger er tiltænkt læger og sundhedspersonale 
Det fuldstændige produktresumé for Quadramet leveres som et separat dokument i produktpakningen 
med henblik på at give sundhedspersonalet yderligere videnskabelige og praktiske oplysninger om 
administration og brug af dette radioaktive lægemiddel. </p>
<p>Der henvises til produktresuméet (produktresuméet skal være inkluderet i pakningen) </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-08cf6fb4c3e579390e3141196404b03b
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for quadramet Package Leaflet for language en"
Description: "ePI document Bundle for quadramet Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-08cf6fb4c3e579390e3141196404b03b"
* entry[0].resource = composition-en-08cf6fb4c3e579390e3141196404b03b

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp08cf6fb4c3e579390e3141196404b03b"
* entry[=].resource = mp08cf6fb4c3e579390e3141196404b03b
                            
                    
Instance: bundlepackageleaflet-da-08cf6fb4c3e579390e3141196404b03b
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for quadramet Package Leaflet for language da"
Description: "ePI document Bundle for quadramet Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-08cf6fb4c3e579390e3141196404b03b"
* entry[0].resource = composition-da-08cf6fb4c3e579390e3141196404b03b

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp08cf6fb4c3e579390e3141196404b03b"
* entry[=].resource = mp08cf6fb4c3e579390e3141196404b03b
                            
                    



Instance: mp08cf6fb4c3e579390e3141196404b03b
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Quadramet 1.3 GBq/mL solution for injection."
Description: "Quadramet 1.3 GBq/mL solution for injection."
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/97/057/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Quadramet 1.3 GBq/mL solution for injection."
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 08cf6fb4c3e579390e3141196404b03bListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "quadramet"

* status = #current
* mode = #working

* title = "List of all ePIs associated with quadramet"

* subject = Reference(mp08cf6fb4c3e579390e3141196404b03b)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#quadramet "quadramet"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-08cf6fb4c3e579390e3141196404b03b) // quadramet en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-08cf6fb4c3e579390e3141196404b03b) // quadramet da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-08cf6fb4c3e579390e3141196404b03b
InstanceOf: List

* insert 08cf6fb4c3e579390e3141196404b03bListRuleset
    